Allogene Therapeutics, Inc.

Thank you for standing by. Welcome to Allogene Therapeutics' fourth quarter 2025 conference call. After the speaker's presentation, there'll be a question and answer session. To ask a question during the session, you'll need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1-1 again. Please be aware that today's conference call is being recorded. I would like to turn the call over to Christine Castellano, Chief Corporate Affairs and Brand Strategy Officer. Ms. Castellano, please go ahead.

Thank you, Operator, and welcome everyone to AllerGene's conference call. After the market closed, AllerGene issued a press release that provided a business update and financial results for the fourth quarter and year-end 2025. This press release and today's webcast are available on our website. Following our prepared remarks, we will host a Q&A session and will aim to keep the call to under an hour. I'm joined today by Dr. David Chang, President and Chief Executive Officer, Dr. Zachary Roberts, Executive Vice President of Research and Development and Chief Medical Officer, and Jeff Parker, Chief Financial Officer. During today's call, we will be making certain forward-looking statements. These may include statements regarding the success and timing of our ongoing and planned clinical trials, data presentations, regulatory filings, future research and development efforts, manufacturing capabilities, the safety and efficacy of our product candidates, commercial market forecasts, and financial guidance, among other things. These forward-looking statements are based on current information, assumptions, and expectations that are subject to change. A description of potential risks can be found in our press release and latest SEC disclosure documents. You are cautioned not to place undue reliance on these forward-looking statements, and Allogene disclaims any obligation to update these statements. I'll now turn the call over to David.

Thank you, Christine. As we close 2025 and enter what we expect to be a defining year for Allogene, the environment around us is shifting. Cell therapy has entered a phase defined by evidence, where progress will be measured not by speculation and promises, but by data and disciplined execution. That shift plays to our strength. Our focus in 2026 is straightforward, delivering meaningful clinical milestones with rigor and speed. This is a year of critical proof points proof points that could validate our allogeneic platform, not merely as an alternative, but as the imperative path to making cell therapy scalable, accessible, and deliverable at biologic-like scale. First, with semicell and alpha-3, we are asking a bold but important question that could redefine the management of large B-cell lymphoma. Can we intervene earlier making CAR-Q truly accessible in the community setting, meaningfully improve outcomes, and alter the course of disease without disrupting the physician's practice. The goals of this study are not about incremental improvement in our late-line setting. It is about shifting the paradigm in the first-line treatment and demonstrating that semicell can reduce the risk of relapse and improve the kill rate. Importantly, it is about expanding access to community cancer centers that historically have been excluded from offering CAR-T, bringing advanced cell therapy to where most patients are treated off the shelf at biologic-like scale. Second, with Allo 3 to 9, we are extending the promise of allogeneic cell therapy to autoimmune disease. Allo329 is a purpose-built dual CD19-CD70 CAR design specifically for immune-mediated conditions, incorporating our Dagger technology to potentially reduce or maybe eliminate traditional lymphodepletion. We expect to report proof-of-concept data in June 2026, and assuming continued progress, another clinical update by the end of the year. We are entering this execution-focused period from a position of financial strength, having extended our runway into the first quarter of 2028. That gives us the ability to advance Alpha-3 and resolution with focus and discipline. We have built a broad and innovative clinical pipeline, but we recognize we cannot advance everything at once. Discipline requires prioritization. Today, we are concentrating our resources on the programs where allogeneic CAR T has the greatest potential to demonstrate what this modality can achieve when developed around its inherent advantages, scalability, accessibility, and ultimately, the potential for durable cure. At the same time, we believe that as the field recognizes that allogeneic CAR-T can deliver at scale with rigor and practicality, it will unlock new opportunities to expand the platform into additional settings and indications. With that, I will turn it over to Zach to walk through the clinical progress in more detail. Thanks, David.